Dec 2022 Medication Monitoring in a Changing Opioid Prescribing Landscape
The new 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain is an update to the most recent practice...
In Practice: Clinical Insights
Nov 2022 Aegis’s Novel Psychoactive Substances Testing Menu Update
In September, Aegis updated both urine and oral fluid novel psychoactive substance (NPS) test menus as a continued commitment to...
Oct 2022 A Brief Look at QTc Prolongation, Serotonin Syndrome, and Tardive Dyskinesia
Introduction Some combinations of medications can lead to serious pharmacodynamic interactions with clinical effects that can be life-threatening in some cases....
Sep 2022 Complexities of Risk Assessment: Opioids, Drug Interactions, & Designer Benzodiazepines
As the number of fatal and non-fatal overdoses continues to rise, we should question why this is occurring. One frequent...
Aug 2022 Behavioral Health: Why Monitor Patients for Medication Adherence?
Mental health illness affects almost a half billion people globally every year including millions of Americans. Data from 2020 showed...
Jul 2022 Novel Psychoactive Substances (NPS): What’s New in 2022
Novel Psychoactive Substances (NPS) are a diverse group of synthetic substances created to mimic the effects of scheduled or illicit...
